TY - JOUR
T1 - Large International Validation of ABSIS and PDAI Pemphigus Severity Scores
AU - French Study Group on Autoimmune Bullous Skin Diseases
AU - Autoimmune Bullous Skin Disease Task Force of the European Academy of Dermatology and Venereology
AU - Hébert, Vivien
AU - Boulard, Claire
AU - Houivet, Estelle
AU - Duvert Lehembre, Sophie
AU - Borradori, Luca
AU - Della Torre, Rocco
AU - Feliciani, Claudio
AU - Fania, Luca
AU - Zambruno, Giovanna
AU - Camaioni, Diana B.
AU - Didona, Biago
AU - Marinovic, Branka
AU - Schmidt, Enno
AU - Schumacher, Nina
AU - Hünefeld, Christian
AU - Schanz, Stefan
AU - Kern, Johannes Steffen
AU - Hofmann, Silke
AU - Bouyeure, Anne Charlotte
AU - Picard-Dahan, Catherine
AU - Prost-Squarcioni, Catherine
AU - Caux, Frederic
AU - Alexandre, Marina
AU - Ingen-Housz-Oro, Saskia
AU - Bagot, Martine
AU - Tancrede-Bohin, Emmanuelle
AU - Bouaziz, Jean David
AU - Franck, Nathalie
AU - Vabres, Pierre
AU - Labeille, Bruno
AU - Richard, Marie Aleth
AU - Delaporte, Emmanuel
AU - Dupuy, Alain
AU - D'Incan, Michel
AU - Quereux, Gaelle
AU - Skowro, François
AU - Paul, Carle
AU - Livideanu, Cristina Bulai
AU - Beylot-Barry, Marie
AU - Doutre, Marie Sylvie
AU - Avenel-Audran, Martine
AU - Bedane, Christophe
AU - Bernard, Philippe
AU - Machet, Laurent
AU - Maillard, Hervé
AU - Jullien, Denis
AU - Debarbieux, Sebastien
AU - Sassolas, Bruno
AU - Misery, Laurent
AU - Abasq, Claire
PY - 2019/1
Y1 - 2019/1
N2 - The Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (ABSIS) scores have been proposed to provide an objective measure of pemphigus activity. These scores have been evaluated only on already treated patients mainly with mild to moderate activity. The objective was to assess the interrater reliability of ABSIS and PDAI scores and their correlation with other severity markers in a large international study. Consecutive patients with newly diagnosed pemphigus were enrolled in 31 centers. Severity scores were recorded during a 24-month period by the same two blinded investigators. Serum was collected at each visit for ELISA measurement of anti-desmoglein antibodies. The intraclass correlation coefficient (ICC) and Spearman rank correlation coefficient were calculated. A total of 116 patients with pemphigus vulgaris (n = 84) or pemphigus foliaceus (n = 32) were included. At baseline, the ABSIS and PDAI ICCs were 0.90 (95% confidence interval [CI] = 0.85–0.93), and 0.91(95% CI = 0.87–0.94), respectively. The ICCs for PDAI were higher in moderate and extensive pemphigus (ICC = 0.82, 95% CI = 0.63–0.92 and ICC = 0.80, 95% CI = 0.62–0.90, respectively) than in patients with intermediate (significant) extent (ICC = 0.50, 95% CI = 0.27–0.68). Conversely, the ICCs for ABSIS were lower in patients with moderate extent (ICC = 0.44, 95% CI = 0.004–0.74) than in those with intermediate or extensive forms, (ICC = 0.69, 95% CI = 0.51–0.81 and ICC = 0.75, 95% CI = 0.51–0.88, respectively). During patients’ follow-up, the ICCs of both ABSIS and PDAI scores remained higher than 0.70. ABSIS and PDAI skin (r = 0.71 and r = 0.75) but not mucosal (r = 0.32 and r = 0.37) subscores were correlated with the evolution of anti-DSG1 and anti-DSG3 ELISA values, respectively. ABSIS and PDAI scores are robust tools to accurately assess pemphigus activity.
AB - The Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (ABSIS) scores have been proposed to provide an objective measure of pemphigus activity. These scores have been evaluated only on already treated patients mainly with mild to moderate activity. The objective was to assess the interrater reliability of ABSIS and PDAI scores and their correlation with other severity markers in a large international study. Consecutive patients with newly diagnosed pemphigus were enrolled in 31 centers. Severity scores were recorded during a 24-month period by the same two blinded investigators. Serum was collected at each visit for ELISA measurement of anti-desmoglein antibodies. The intraclass correlation coefficient (ICC) and Spearman rank correlation coefficient were calculated. A total of 116 patients with pemphigus vulgaris (n = 84) or pemphigus foliaceus (n = 32) were included. At baseline, the ABSIS and PDAI ICCs were 0.90 (95% confidence interval [CI] = 0.85–0.93), and 0.91(95% CI = 0.87–0.94), respectively. The ICCs for PDAI were higher in moderate and extensive pemphigus (ICC = 0.82, 95% CI = 0.63–0.92 and ICC = 0.80, 95% CI = 0.62–0.90, respectively) than in patients with intermediate (significant) extent (ICC = 0.50, 95% CI = 0.27–0.68). Conversely, the ICCs for ABSIS were lower in patients with moderate extent (ICC = 0.44, 95% CI = 0.004–0.74) than in those with intermediate or extensive forms, (ICC = 0.69, 95% CI = 0.51–0.81 and ICC = 0.75, 95% CI = 0.51–0.88, respectively). During patients’ follow-up, the ICCs of both ABSIS and PDAI scores remained higher than 0.70. ABSIS and PDAI skin (r = 0.71 and r = 0.75) but not mucosal (r = 0.32 and r = 0.37) subscores were correlated with the evolution of anti-DSG1 and anti-DSG3 ELISA values, respectively. ABSIS and PDAI scores are robust tools to accurately assess pemphigus activity.
UR - http://www.scopus.com/inward/record.url?scp=85054345231&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2018.04.042
DO - 10.1016/j.jid.2018.04.042
M3 - Scientific review articles
C2 - 30301637
AN - SCOPUS:85054345231
SN - 0022-202X
VL - 139
SP - 31
EP - 37
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 1
ER -